The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Activated T Cell Exosomes Promote Tumor Invasion via Fas Signaling Pathway
Abstract
Activated T cells release bioactive Fas ligand (FasL) in exosomes, which subsequently induce self-apoptosis of T cells. However, their potential effects on cell apoptosis in tumors are still unknown. In this study, we purified exosomes expressing FasL from activated CD8+ T cell from OT-I mice and found that activated T cell exosomes had little effect on apoptosis and proliferation of tumor cells but promoted the invasion of B16 and 3LL cancer cells in vitro via the Fas/FasL pathway. Activated T cell exosomes increased the amount of cellular FLICE inhibitory proteins and subsequently activated the ERK and NF-κB pathways, which subsequently increased MMP9 expression in the B16 murine melanoma cells. In a tumor-invasive model in vivo, we observed that the activated T cell exosomes promoted the migration of B16 tumor cells to lung. Interestingly, pretreatment with FasL mAb significantly reduced the migration of B16 tumor cells to lung. Furthermore, CD8 and FasL double-positive exosomes from tumor mice, but not normal mice, also increased the expression of MMP9 and promoted the invasive ability of B16 murine melanoma and 3LL lung cancer cells. In conclusion, our results indicate that activated T cell exosomes promote melanoma and lung cancer cell metastasis by increasing the expression of MMP9 via Fas signaling, revealing a new mechanism of tumor immune escape.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,938
Johnstone, R. M., Adam, M., Hammond, J. R., Orr, L., & Turbide, C. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48095-7 · Cited by 2,931
The CD95(APO-1/Fas) DISC and beyond
Peter, M. E., & Krammer, P. H. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401186 · Cited by 1,080
Apoptosis signaling by death receptors
Schulze‐Osthoff, K., Ferrari, D., Los, M., Wesselborg, S., & Peter, M. E. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2540439.x · Cited by 978
NF-κB Signals Induce the Expression of c-FLIP
Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K., & Tschopp, J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.16.5299-5305.2001 · Cited by 813
FAP-1: A Protein Tyrosine Phosphatase That Associates with Fas
Sato, T., Irie, S., Kitada, S., & Reed, J. C. (1995) · Science · doi:10.1126/science.7536343 · Cited by 683
Activation‐induced cell death in T cells
Green, D. R., Droin, N., & Pinkoski, M. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00051.x · Cited by 647
c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis
Chang, D. W. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf356 · Cited by 563
Exosomes: immune properties and potential clinical implementations
Chaput, N., & Théry, C. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-010-0233-9 · Cited by 560
The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways
Kataoka, T., Budd, R. C., Holler, N., Thome, M., Martinon, F., Irmler, M., Burns, K., Hahne, M., Kennedy, N., Kovacsovics, M., et al. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00512-1 · Cited by 552
Cited by
Biological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926
Extracellular vesicles: biology and emerging therapeutic opportunities
EL Andaloussi, S., Mäger, I., Breakefield, X. O., & Wood, M. J. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3978 · Cited by 3,571
In Vivo Imaging Reveals Extracellular Vesicle-Mediated Phenocopying of Metastatic Behavior
Zomer, A., Maynard, C., Verweij, F. J., Kamermans, A., Schäfer, R., Beerling, E., Schiffelers, R. M., de Wit, E., Berenguer, J., Ellenbroek, S. I. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.042 · Cited by 869
Exosomes in cancer: small particle, big player
Zhang, X., Yuan, X., Shi, H., Wu, L., Qian, H., & Xu, W. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0181-x · Cited by 780
Exosomes and other extracellular vesicles in host–pathogen interactions
Schorey, J. S., Cheng, Y., Singh, P. P., & Smith, V. L. (2015) · EMBO reports · doi:10.15252/embr.201439363 · Cited by 727
Exosomes─Nature’s Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics
Tenchov, R., Sasso, J. M., Wang, X., Liaw, W.-S., Chen, C.-A., & Zhou, Q. A. (2022) · ACS Nano · doi:10.1021/acsnano.2c08774 · Cited by 604
Exosomes and their roles in immune regulation and cancer
Greening, D. W., Gopal, S. K., Xu, R., Simpson, R. J., & Chen, W. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.02.009 · Cited by 597
Exosome-based immunotherapy: a promising approach for cancer treatment
Xu, Z., Zeng, S., Gong, Z., & Yan, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01278-3 · Cited by 482
Wang, J., Hendrix, A., Hernot, S., Lemaire, M., De Bruyne, E., Van Valckenborgh, E., Lahoutte, T., De Wever, O., Vanderkerken, K., & Menu, E. (2014) · Blood · doi:10.1182/blood-2014-03-562439 · Cited by 441
Self-citationExosomes: new molecular targets of diseases
Samanta, S., Rajasingh, S., Drosos, N., Zhou, Z., Dawn, B., & Rajasingh, J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.162 · Cited by 425
The role of CD95 and CD95 ligand in cancer
Peter, M. E., Hadji, A., Murmann, A. E., Brockway, S., Putzbach, W., Pattanayak, A., & Ceppi, P. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.3 · Cited by 357
The role of exosomal PD-L1 in tumor progression and immunotherapy
Xie, F., Xu, M., Lu, J., Mao, L., & Wang, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1074-3 · Cited by 348
Ye, S.-B., Li, Z.-L., Luo, D.-H., Huang, B.-J., Chen, Y.-S., Zhang, X.-S., Cui, J., Zeng, Y.-X., & Li, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2118 · Cited by 346
Transfer of extracellular vesicles during immune cell‐cell interactions
Gutiérrez‐Vázquez, C., Villarroya‐Beltri, C., Mittelbrunn, M., & Sánchez‐Madrid, F. (2013) · Immunological Reviews · doi:10.1111/imr.12013 · Cited by 323
Host Matrix Modulation by Tumor Exosomes Promotes Motility and Invasiveness
Mu, W., Rana, S., & Zöller, M. (2013) · Neoplasia · doi:10.1593/neo.13786 · Cited by 248
“[43] Cai Z, Yang F, Yu L, Yu Z, Jiang L, Wang Q, Yang Y, Wang L, Cao X, and”
BackgroundExtracellular Vesicles in Liver Pathobiology: Small Particles With Big Impact
Hirsova, P., Ibrahim, S. H., Verma, V. K., Morton, L. A., Shah, V. H., LaRusso, N. F., Gores, G. J., & Malhi, H. (2016) · Hepatology · doi:10.1002/hep.28814 · Cited by 229
Emerging roles and therapeutic value of exosomes in cancer metastasis
Wu, M., Wang, G., Hu, W., Yao, Y., & Yu, X.-F. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0964-8 · Cited by 140
Analysis of extracellular vesicles as emerging theranostic nanoplatforms
Xing, Y., Cheng, Z., Wang, R., Lv, C., James, T. D., & Yu, F. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213506 · Cited by 67
Lopes, D., Lopes, J., Pereira-Silva, M., Peixoto, D., Rabiee, N., Veiga, F., Moradi, O., Guo, Z.-H., Wang, X.-D., Conde, J., et al. (2023) · Military Medical Research · doi:10.1186/s40779-023-00453-z · Cited by 36
Tumor–Stromal Cell Communication: Small Vesicles Signal Big Changes
Wendler, F., Stamp, G. W., & Giamas, G. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.05.007 · Cited by 32
“Q3 upregulation of MMP9 [2] (Figure 2).”
Liquid biopsy: creating opportunities in brain space
Trivedi, R., & Bhat, K. P. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02446-0 · Cited by 27
Metadata
- Authors
- Cai, Z., Yang, F., Yu, L., Yu, Z., Jiang, L., Wang, Q., Yang, Y., Wang, L., Cao, X., & Wang, J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-06
- Volume
- 188
- Issue
- 12
- Pages
- 5954-5961
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2110964883
- Cited by
- 265
- References
- 46
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.